Bausch Health Announces 2026 Annual Meeting of Shareholder Results

Bausch Health (NYSE:BHC) reported results of its 2026 Annual Meeting of Shareholders held on May 19, 2026.

Rhea-AI Summary

Bausch Health (NYSE:BHC) reported results of its 2026 Annual Meeting of Shareholders held on May 19, 2026. All 10 director nominees were elected, including new director Eiry W. Roberts, M.D., who will chair the Science and Technology Committee.

Shareholders approved, on a non-binding basis, executive compensation, and confirmed PricewaterhouseCoopers LLP as auditor until the 2027 annual meeting, authorizing the board to set auditor remuneration. Final vote totals will be disclosed in a Form 8-K filing.

Argus May 20 session

+3.38% close to close Open Argus

Details

News Market Reaction – BHC

On May 20, the first trading day after this news, BHC closed 3.38% above the previous close.

Data tracked by StockTitan Argus for the May 20 session.

Market Context

This announcement confirms all 10 director nominees were elected and that shareholders approved exec...

Analysis

This announcement confirms all 10 director nominees were elected and that shareholders approved executive compensation and the appointment of the external auditor through the 2027 meeting. It follows a quarter marked by strong revenue but a large goodwill impairment and a shift to a shareholders’ equity deficit, as disclosed in recent SEC filings. Investors monitoring this update may focus on how board composition, governance decisions and upcoming earnings reports interact with the company’s existing leverage and cash-flow objectives.

Key Figures

Directors elected: 10 directors Votes for Appio: 196,814,621 Votes withheld Appio: 2,743,810 +5 more

Directors elected

10 directors

2026 Annual Meeting of Shareholders

Votes for Appio

196,814,621

Votes "For" director Thomas J. Appio

Votes withheld Appio

2,743,810

Votes "Withheld" for Thomas J. Appio

Broker non-votes

79,859,605

Broker non-votes recorded for each director item

Votes for Roberts

196,972,752

Votes "For" new director Eiry W. Roberts, M.D.

Votes withheld Roberts

2,585,679

Votes "Withheld" for Eiry W. Roberts, M.D.

Auditor term

Through 2027 meeting

PwC appointed until close of 2027 Annual Meeting

Meeting date

May 19, 2026

Date of 2026 Annual Meeting of Shareholders

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   Conference participation

   24h Move

   -2.2%

   Management highlighted upcoming appearance at RBC healthcare investor conference.

2. May 12

   Conference participation

   24h Move

   -2.2%

   Announcement of fireside chat at Barclays leveraged finance conference.

3. Apr 29

   Quarterly earnings

   24h Move

   +2.3%

   Q1 2026 results with revenue growth and large goodwill impairment charge.

4. Apr 14

   Product launch

   24h Move

   -0.7%

   Launch of Biafine Skin Recovery Emulsion via U.S. online channels.

5. Mar 31

   Earnings date set

   24h Move

   +7.4%

   Company scheduled Q1 2026 earnings release and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

broker non-votes, non-binding advisory vote, Form 8-K

3 terms

broker non-votes financial

"Name | | For | | Withheld | | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

non-binding advisory vote regulatory

"Shareholders also approved, on a non-binding advisory vote, the compensation"

A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.

Form 8-K regulatory

"reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.

Detailed results of the vote follow:

Name		For		Withheld		Broker Non-Votes
Thomas J. Appio		196,814,621		2,743,810		79,859,605
Christian A. Garcia		196,711,908		2,846,523		79,859,605
Michael Goettler		196,757,828		2,800,603		79,859,605
Sarah B. Kavanagh		188,459,870		11,098,561		79,859,605
Frank D. Lee		183,885,617		15,672,814		79,859,605
Sandra Leung		195,931,772		3,626,659		79,859,605
John A. Paulson		196,214,806		3,343,625		79,859,605
Robert N. Power		186,236,066		13,322,365		79,859,605
Eiry W. Roberts, M.D.		196,972,752		2,585,679		79,859,605
Amy B. Wechsler, M.D.		195,813,955		3,744,476		79,859,605

Shareholders also approved, on a non-binding advisory vote, the compensation of the Company's named executive officers, appointment of PricewaterhouseCoopers LLP to serve as the Company's auditor until the close of the Company's 2027 Annual Meeting of Shareholders, and the authorization for the board of directors to fix the auditor's remuneration.

The final vote tabulation on all matters voted on at the Annual Meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company's website at www.bauschhealth.com.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. 

Investor Contact:	Media Contact:
Garen Sarafin	Katie Savastano
ir@bauschhealth.com	corporate.communications@bauschhealth.com
(877) 281-6642 (toll free)	(908) 569-3692
BHC-AGM

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-2026-annual-meeting-of-shareholder-results-302776740.html

SOURCE Bausch Health Companies Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the key outcomes of the Bausch Health (BHC) 2026 annual meeting?

Shareholders elected all 10 director nominees and approved executive pay on an advisory basis. According to Bausch Health, they also reappointed PricewaterhouseCoopers LLP as auditor through the 2027 meeting and authorized the board to fix auditor remuneration.

Who is the new director elected at the Bausch Health (BHC) 2026 annual meeting?

Shareholders elected Eiry W. Roberts, M.D. as a new director. According to Bausch Health, Dr. Roberts brings pharmaceutical leadership experience and will serve as chair of the board’s Science and Technology Committee.

How did Bausch Health (BHC) shareholders vote on executive compensation in 2026?

Bausch Health shareholders approved, on a non-binding advisory vote, compensation for the company’s named executive officers. According to Bausch Health, this say-on-pay resolution passed alongside director elections and auditor appointment matters.

Which auditor did Bausch Health (BHC) shareholders appoint at the 2026 annual meeting?

Shareholders appointed PricewaterhouseCoopers LLP as Bausch Health’s auditor until the 2027 annual meeting. According to Bausch Health, investors also authorized the board of directors to fix the auditor’s remuneration for this engagement period.

Where can investors find the full voting results of the Bausch Health (BHC) 2026 annual meeting?

Detailed vote tabulations will be filed with the SEC on Form 8-K. According to Bausch Health, this report will also appear on the company’s SEDAR+ profile and its website at www.bauschhealth.com for investor access.